On March 28, 2025, the AstraZeneca-CICC Healthcare Industry Fund Limited Partners Meeting was successfully held in Qingdao. Under the theme “New Dynamics, High Aspirations: Setting Sail for Progress,” representatives from AstraZeneca, CICC Capital, industry experts, fund limited partners, and portfolio companies gathered to explore cutting-edge trends and development directions in the healthcare sector.
Precision Planning, Collaborative Drive. As the first portfolio company of the AstraZeneca-CICC Qingdao Sub-Fund, bioGenous has not only secured strategic investment support from AstraZeneca and CICC Capital but also established a solid cooperative foundation with AstraZeneca in organoid-based new drug development. Moving forward, bioGenous will intensify its focus on frontier technological breakthroughs in organoids, innovative application model development, and the construction of high-standard, high-capacity pipelines. With the mission of being a “global pioneer in organoid model platforms”, the company will comprehensively expand into overseas markets, accelerate the deployment of “end-to-end, globalized” products and services, and advance the application of this emerging technology within the global pharmaceutical industry. This initiative aims to propel the rapid development of life science research and the pharmaceutical sector.
About the AstraZeneca-CICC Healthcare Industry Fund (AZ-CICC Industry Fund)
The AstraZeneca-CICC Healthcare Industry Fund is a private equity fund jointly established by AstraZeneca and CICC Capital, specializing in investments within the healthcare industry. Integrating AstraZeneca's global industrial strengths with CICC Capital's extensive capital operation expertise, the fund focuses on investment areas including biopharmaceuticals, medical devices, diagnostic services, and digital healthcare. It is committed to pooling industrial and financial resources to provide bidirectional empowerment—from R&D to commercialization—for enterprises and investment partners, jointly advancing innovation and development in China's healthcare industry.
